scholarly journals Number of musculoskeletal pain sites leads to increased long-term healthcare contacts and healthcare related costs – a Danish population-based cohort study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
S. Mose ◽  
P. Kent ◽  
A. Smith ◽  
J. H. Andersen ◽  
D. H. Christiansen
Keyword(s):  
Cohort Study ◽  
Musculoskeletal Pain ◽  
Health Anxiety ◽  
Population Based ◽  
Care Seeking ◽  
Healthcare Use ◽  
Danish Population ◽  
Term Care ◽  
Pain Site

Abstract Background People with musculoskeletal pain seek more healthcare than the general population, however little is known about the long-term effect on healthcare use. The aim of this study was to examine the consequences of number of musculoskeletal pain sites on long-term care-seeking and healthcare-related costs and explore how health anxiety influences this relationship. Methods We conducted a Danish population-based longitudinal cohort study of 4883 participants combining self-reported survey data from 2008 with ten-year follow-up data from national health registers. Using a causal inference framework, we examined associations between number of pain sites (range 0–7)/level of health anxiety (high/low level) and face-to-face healthcare contacts/healthcare-related costs. Data were analyzed using negative binomial regression with generalized estimating equations. Regression models were adjusted for sex, age, duration of pain, level of education, comorbidity, personality traits, risk of depression, marital status, physical job exposure, and previous healthcare utilization. Results For each additional pain site general healthcare contacts (Incidence Rate Ratio (IRR): 1.04 (95% CI: 1.03–1.05)), healthcare-related costs (IRR: 1.06 (95% CI: 1.03–1.08) and musculoskeletal healthcare contacts (IRR: 1.11 (95% CI:1.09–1.14) increased. Those with high levels of health anxiety at baseline had a slightly higher number of general healthcare contacts (IRR 1.06 (1.01–1.11), independent of number of pain sites. However, level of anxiety did not influence the effect of number of pain sites on any healthcare use or cost outcomes. Conclusions We found evidence for a causal association between increasing number of pain sites and greater healthcare use and cost, and high levels of health anxiety did not increase the strength of this association. This suggests that number of pain sites could be a potential target for biopsychosocial interventions in order to reduce the need for future care-seeking.

scholarly journals Hematuria and subsequent long-term risk of end-stage kidney disease: A Danish population-based cohort study

2021 ◽  
Author(s):  
Kristine Fogh ◽  
Søren Viborg Vestergaard ◽  
Christian Fynbo Christiansen ◽  
Lars Pedersen ◽  
Dorothea Nitsch ◽  
...  
Keyword(s):  
Cohort Study ◽  
Kidney Disease ◽  
Population Based ◽  
Danish Population ◽  
End Stage Kidney Disease ◽  
End Stage

scholarly journals Vaccine effectiveness after 1st and 2nd dose of the BNT162b2 mRNA Covid-19 Vaccine in long-term care facility residents and healthcare workers – a Danish cohort study

2021 ◽  
Author(s):  
Ida Rask Moustsen-Helms ◽  
Hanne-Dorthe Emborg ◽  
Jens Nielsen ◽  
Katrine Finderup Nielsen ◽  
Tyra Grove Krause ◽  
...  
Keyword(s):  
Cohort Study ◽  
Healthcare Workers ◽  
Long Term Care ◽  
Care Facility ◽  
Dose Schedule ◽  
Population Based ◽  
Vaccine Effectiveness ◽  
Calendar Time ◽  
Term Care

AbstractBackgroundAt the end of 2020, Denmark launched an immunization program against SARS-CoV-2. The Danish health authorities prioritized persons currently living in long-term care facilities (LTCF residents) and frontline healthcare workers (HCW) as the first receivers of vaccination. Here we present preliminary population based vaccine effectiveness (VE) estimates in these two target groups.MethodsThe study was designed as a retrospective registry- and population-based observational cohort study including all LTCF residents and all HWC. The outcome was a polymerase chain reaction confirmed SARS-CoV-2, and VE was estimated for different periods following first and second dose. We used Poisson and Cox regressions to estimate respectively crude and calendar time-adjusted VE for the BNT162b2 mRNA Covid-19 Vaccine from Pfizer/BioNTech with 95% confidence intervals (CI) for vaccinated versus unvaccinated.ResultsA total of 39,040 LTCF residents (median age at first dose; 84 years, Interquartile range (IQR): 77-90) and 331,039 HCW (median age at first dose; 47 years, IQR: 36-57) were included. Among LTCF residents, 95.2% and 86.0% received first and second dose from 27 December 2020 until 18 February 2021, for HWC the proportion was 27.8% and 24.4%. During a median follow-up of 53 days, there were 488 and 5,663 confirmed SARS-CoV-2 cases in the unvaccinated groups, whereas there were 57 and 52 in LTCF residents and HCW within the first 7 days after the second dose and 27 and 10 cases beyond seven days of second dose. No protective effect was observed for LTCF residents after first dose. In HCW, VE was 17% (95% CI; 4-28) in the > 14 days after first dose (before second dose). Furthermore, the VE in LTCF residents at day 0-7 of second dose was 52% (95% CI; 27-69) and 46% (95% CI; 28-59) in HCW. Beyond seven days of second dose, VE increased to 64% (95% CI; 14-84) and 90% (95% CI; 82-95) in the two groups, respectively.ConclusionThe results were promising regarding the VE both within and beyond seven days of second vaccination with the BNT162b2 mRNA Covid-19 Vaccine currently used in many countries to help mitigate the global SARS-CoV-2 pandemic.Impact of the researchSo far, observational studies of the real-word effectiveness of the mRNA Vaccine BNT162b2 has been limited to the period after the administration of the first dose. This is the first report to date to present vaccine effectiveness (VE) estimates after the second BNT162b2 mRNA Covid-19 Vaccine. We estimated a VE of 52% and 46% in LTCF residents and HCW within seven days, which increased to 64% and 90% in the two groups respectively beyond seven days of immunization. These findings supports maintaining a two-dose schedule of the BNT162b2 mRNA Covid-19 Vaccine.

scholarly journals Impact of chemotherapy delay on short- and long-term survival in younger and older AML patients: a Danish population-based cohort study

Leukemia ◽  
2014 ◽  
Vol 28 (9) ◽  
pp. 1926-1929 ◽  
Author(s):  
L S G Østgard ◽  
J M Nørgaard ◽  
H Sengeløv ◽  
M S Holm ◽  
M K Jensen ◽  
...  
Keyword(s):  
Cohort Study ◽  
Population Based ◽  
Danish Population ◽  
Term Survival ◽  
Long Term Survival ◽  
Short And Long Term

scholarly journals Effect of Nephrology Care on Mortality in Incident Dialysis Patients: A Population-Based Cohort Study

2021 ◽  
Vol 11 (11) ◽  
pp. 1071
Author(s):  
Cheng-Yin Chung ◽  
Ping-Hsun Wu ◽  
Yi-Wen Chiu ◽  
Shang-Jyh Hwang ◽  
Ming-Yen Lin
Keyword(s):  
Cohort Study ◽  
Critical Period ◽  
Causal Effect ◽  
Population Based ◽  
Term Care ◽  
Mortality Hazard ◽  
Nephrology Care ◽  
One Year ◽  
Intermittent Care

Long-term and continuous nephrology care effects on post-dialysis mortality remain unclear. This study aims to systematically explore the causal effect of nephrology care on mortality for patients with dialysis initiation. We conducted a retrospective cohort study to include incident patients with dialysis for ≥ 3 months in Taiwan from 2004 through 2011. The continuous nephrology care of incident patients in the three years before their dialysis was measured every six months. Continuous nephrology care was determined by 0–6, 0–12, …, 0–36 months and their counterparts; and none, intermittent, 0–6 months, …, and 0–36 months. Simple and weighted hazards ratio (HR) and 95% confidence interval (CI) for one-year mortality were estimated after propensity score (PS) matching. We included a total of 44,698 patients (mean age 63.3 ± 14.2, male 51.9%). Receiving ≥ 1 year predialysis nephrology care was associated with a 22% lower post-dialysis mortality hazard. No different effects were found (ranges of PS matching HR: 0.77–0.80) when comparing the defined duration of nephrology care with their counterparts. Stepped survival benefits were newly identified in the intermittent care, which had slightly lower HRs (weighted HR: 0.88, 95% CI: 0.79–0.97), followed by reviving care over six months to two years (ranges of weighted HR: 0.60–0.65), and reviving care over two years (ranges of weighted HR: 0.48–0.52). There was no existing critical period of nephrology care effect on post-dialysis, but there were extra survival benefits when extending nephrology care to >2 years, which suggests that continuous and long-term care during pre-dialysis/chronic kidney disease phase is required.

Sign in / Sign up

Export Citation Format

Share Document